Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Posaconazole.

Elizabeth S Dodds Ashley1, Barbara D Alexander

  • 1Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

Drugs of Today (Barcelona, Spain : 1998)
|August 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Multisystem <i>Lomentospora prolificans</i> progression on fosmanogepix despite <i>in vitro</i> activity: a call for expanding clinical research on novel antifungals.

ASM case reports·2026
Same author

Fungal diagnostic stewardship in immunocompromised populations: a focus on molds and dimorphic fungi.

Clinical microbiology reviews·2026
Same author

Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis.

Mycopathologia·2026
Same author

Healthcare Resource Utilization, Treatment Costs, and Mortality in Patients with Malignancies or Transplantation Who Develop Invasive Aspergillosis.

Journal of fungi (Basel, Switzerland)·2025
Same author

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

The Lancet. Infectious diseases·2025
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

New antifungal posaconazole shows promise for treating invasive fungal infections in complex patients. It offers a broader spectrum of activity and better tolerability than existing options.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) are increasing due to advances in immunosuppressive therapies.
  • Current antifungal treatments have limitations in spectrum of activity and toxicity.
  • Complex patient populations require novel therapeutic options.

Purpose of the Study:

  • To investigate the efficacy and safety of posaconazole for treating IFIs.
  • To evaluate posaconazole's expanded spectrum of activity against yeasts and molds.
  • To compare posaconazole's tolerability with existing systemic antifungal agents.

Main Methods:

  • Clinical investigations of posaconazole in patients with IFIs.
  • In vitro susceptibility testing against various fungal pathogens.

Related Experiment Videos

  • Comparative safety and tolerability assessments.

    • Main Results:

    • Posaconazole demonstrates potent activity against fluconazole-resistant Candida and Aspergillus species.
    • It also shows activity against Zygomycetes, a challenging group of fungi.
    • Posaconazole exhibits a favorable tolerability profile with diminished toxicity compared to other systemic antifungals.

    Conclusions:

    • Posaconazole is a promising new triazole antifungal agent.
    • It offers an expanded spectrum of activity and improved safety profile.
    • Further clinical trials are needed to define its definitive role in managing IFIs.